Pathalys Pharma
Raleigh
About Pathalys Pharma
Pathalys is a clinical biopharmaceutical company that develops therapeutics that improve late-stage chronic kidney disease. Pathalys' initial focus will be on improving treatment for secondary hyperparathyroidism, which is an unmet need (SHPT). SHPT is a condition in which a disease outside of the parathyroid glands causes all of the parathyroid glands to swell and become hyperactive, producing an excessive amount of parathyroid hormone (PTH).
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $100K – $500K
- Total funding: $266.0M
- Funding stage: Early Stage Venture
- Last round: Series B (Aug 2024)
- Website: pathalys.com
- Phone: [email protected]
Industries & Categories
Biopharma, Biotechnology, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/pathalys-pharma-115420 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.